TrialRheumatology (Oxford, England)2025

A phase 2 randomized trial of safety and pharmacokinetics of IgPro20 and IgPro10 in patients with diffuse cutaneous systemic sclerosis.

Christopher P Denton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.